851138-04-0

Basic information

• Product Name: 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide
• Synonyms: 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide
• CAS NO: 851138-04-0
• Molecular Weight: 449.435
• Mol File: 851138-04-0.mol

Chemical Properties

• CAS DataBase Reference: 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide(851138-04-0)
• EPA Substance Registry System: 4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-N-(3-(trifluoromethyl)phenyl)benzamide(851138-04-0)

Safety Data

• Hazardous Substances Data: 851138-04-0(Hazardous Substances Data)

Upstream product

• 641569-95-1 C₁₁H₁₅N₃O₂ 
• 641569-94-0 4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}benzoic acid 
• 641569-97-3 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]benzoic acid ethyl ester 
• 641569-96-2 3-guanidino-4-methylbenzoic acid ethyl ester nitrate 
• 1205540-17-5 4-methyl-3-[[4-(3-pyridyl)-2-pyrimidinyl]amino]benzoyl chloride 
• 98-16-8 3-trifluoromethylaniline 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 2458-12-0 3-amino-p-toluic acid 

Relevant articles and documents

HETEROCYCLIC INHIBITORS OF PCSK9

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, PCSK9, or a pharmaceutically acceptable salt, solvate, prodrug or polymorph thereof, and to compositions and formulations comprising such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I): (I) wherein A, D and Q are described herein.

Design, synthesis and biological evaluation of pyridin-3-yl pyrimidines as potent Bcr-Abl inhibitors

A series of pyridin-3-yl pyrimidines was synthesized and evaluated for their Bcr-Abl inhibitory and anticancer activity. The preliminary results indicated that some compounds were promising anticancer agents. Compounds A2, A8, and A9 exhibited potent Bcr-Abl inhibitory activity, suggesting that aniline containing halogen substituents might be important for biological activity. Molecular docking was carried out to investigate the binding mode of them with Bcr-Abl. Details of synthesis and SAR studies of these compounds are described. A series of phenylaminopyrimidines was designed and synthesized as potent Bcr-Abl inhibitors. The screening of these rationally designed compounds for antitumor activity had identified three candidate leads which could be further optimized to improve the anticancer activities.

COMBINATIONS COMPRISING BCR-ABL/C-KIT/PDGF-R TK INHIBITORS FOR TREATING CANCER

The invention relates to a combination comprising a Bcr-Abl, c-Kit and PDGF-R tyrosine kinase inhibitor; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination.